• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
XU Junjun,ZENG Caifang.Efficacy and safety of Febuxostat and Allopurinol in hyperuricemia after renal transplantation[J].Journal Of Pharmaceutical Research,2021,40(3):206-207,210[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2506times   Download 2366次 QR Code for this article
Scan with your phone!
肾移植术后高尿酸血症应用非布司他和别嘌醇的有效性与安全性
徐君君,曾彩芳
Font:Larger+|Default|Smaller-
(广州医科大学附属第二医院药学部,广东 广州 511447)
摘要:
目的 对应用不同降尿酸药物的肾移植术后高尿酸血症患者分析,比较非布司他与别嘌醇治疗肾移植术后高尿酸血症的有效性与安全性。方法 回顾肾移植术后高尿酸血症患者的降尿酸治疗方案,按使用的降尿酸药物不同,分成两组,非布司他组和别嘌醇组,分别分析患者的尿酸控制水平,对比分析两组的区别。结果 非布司他组尿酸水平远低于别嘌醇组,成组t检验P<0.05,两组差异具有统计学意义。结论 肾移植术后高尿酸血症患者,应用非布司他组的尿酸水平控制优于别嘌醇组。同时根据大量文献数据,在应用非布司他或其他降尿酸药物应密切监测患者相关指标及不良反应,尤其对于肾移植术后患者。
关键词:  肾移植术后  高尿酸血症  别嘌醇  非布司他  不良反应
DOI:10.13506/j.cnki.jpr.2021.03.015
基金项目:
Efficacy and safety of Febuxostat and Allopurinol in hyperuricemia after renal transplantation
XU Junjun,ZENG Caifang
(Department of Pharmacy, The Second Affiliated Hospital of Guangzhou Medical University,Guangzhou 511447, China)
Abstract:
Objective To analyze the patients with hyperuricemia after renal transplantation with different drugs, to compare the efficacy and safety of febuxostat and allopurinol in the treatment of hyperuricemia after renal transplantation.Methods Review the treatment of hyperuricemia after renal transplantation, according to the use of different antiuricemic drugs, the patients were divided into two groups: febuxostat group and allopurinol group. The control level of uric acid was analyzed and the differences between the two groups were compared. Results The level of uric acid in the febuxostat group was much lower than that in the allopurinol group, and the difference between the two groups was statistically significant (P<0.05). Conclusion The control of uric acid level in the febuxostat group was better than that in the allopurinol group in the patients with hyperuricemia after renal transplantation. At the same time, according to a large number of literature data, we should closely monitor the relevant indicators and adverse reactions of patients during the application of febuxostat or any other antiduricemic drugs, especially for patients after renal transplantation.
Key words:  Renal transplantation  Hyperuricemia  Allopurinol  Febuxostat  Adverse reaction
Today's Visits:483    Total Visits:2383194
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.